Generic Name for IPRIVASK
Desirudin 15mg/vial; pwd for SC inj after reconstitution; preservative-free; diluent contains mannitol.
Legal Classification:
Rx
Pharmacological Class for IPRIVASK
Direct thrombin inhibitor (recombinant hirudin).
Manufacturer of IPRIVASK
Canyon Pharmaceuticals
Indications for IPRIVASK
DVT prophylaxis in patients undergoing hip replacement surgery.
Adult dose for IPRIVASK
Not interchangeable with other hirudins. Give by SC inj, preferably in abdomen or thigh. 15mg every 12hours starting up to 5–15min before surgery (after induction of regional block anesthesia, if used); may continue for 9–12 days post-op. Renal impairment (CrCl<60mL/min): reduce dose (see literature).
Children's dosing for IPRIVASK
Not recommended.
Warnings/Precautions for IPRIVASK
Renal impairment: monitor aPTT and serum creatinine closely. Hemorrhagic stroke. Diabetic retinopathy. Severe uncontrolled hypertension. Recent GI or pulmonary bleeding. Recent surgery or biopsy. Neuraxial puncture. Post-op indwelling epidural catheter (place catheter before starting therapy and remove when desirudin effect is low). Bacterial endocarditis. Hepatic impairment. Monitor for neurological impairment (may indicate spinal/epidural hematoma). Pregnancy (Cat.C). Nursing mothers.
Interactions for IPRIVASK
Concomitant heparins (fractionated or unfractionated): not recommended. Concomitant NSAIDs, platelet inhibitors, other anticoagulants: increased risk of bleeding, neuraxial hematoma with epidural catheters; discontinue these and others that increase bleeding risk (eg, glucocorticoids, Dextran 40) before starting desirudin. Caution with drugs that affect platelets (eg, salicylates, ticlopidine, clopidogrel, abciximab, gp IIb/IIIa antagonists). Switching to or from coumadin: monitor closely.
Adverse Reactions for IPRIVASK
Bleeding, inj site reaction/mass, nausea, anaphylaxis, antibody formation.
How is IPRIVASK supplied?
Single-use vials—10 (w. diluent, supplies)
Related Disease:
Coagulation disorders
Iprivask被认为是优于肝素及低分子肝素（低分子肝素），依诺肝素预防深静脉血栓近端静脉血栓和重大的事件（VTE）的的后择期髋关节置换手术。静脉血栓栓塞，其中最常见的并发症，手术患者，会增加住院费用，住院天数，发病率和死亡率。
维克Tapson，医学博士，医学教授，杜克大学，说：“Desirudin是一个重要的进步，并有望成为一个有价值的替代肝素预防深静脉血栓形成的药物。”
很少有替代品存在肝素的抗凝预防深静脉血栓患者在住院。VTE的预防治疗肝素的抗凝血剂，可以通过各种复杂的突发事件，包括血小板减少症，已证实会增加短期死亡率。血小板减少症的发展往往导致暂停与肝素预防静脉血栓栓塞患者无保护的离开了一段时间，由于缺乏替代品。
“中存在的重大需要美国替代肝素的抗凝血剂是更有效和更容易使用比现有贸易一体化分析研究。Desirudin成为可用是朝这个方向前进的一步，”克雷格说凯斯勒博士，乔治敦大学医学教授和病理学及血液学组长。
凯斯勒指出，由于Iprivask是管理作为一个固定的皮下剂量，“这是易于使用静脉贸易一体化分析研究，并提供一个更安全的替代深静脉血栓的预防。”
“Iprivask是一种很有前途的进步，因为它是优于现行标准的护理在预防静脉血栓栓塞近端深静脉血栓形成和主要的，没有差异出血，”贝尔说：黎明，药学博士，高级副总裁兼总经理峡谷药品。“这不会有风险血小板减少症或肝素诱导的血小板减少症，是相对短效，易于监控。”
“我们很高兴能够推出第一个新的深静脉血栓预防剂在近10年来，说：”。生金麻将，总裁，峡谷药品“Iprivask是一个重要的除了深静脉血栓的预防医疗设备，因为预防深静脉血栓形成的选项是有限的，尤其是在在围手术期的设置。“
完整资料附件：http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=42195